Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$31.61
+0.2%
$32.42
$20.20
$43.11
$1.56B1.56602,702 shs101,378 shs
Atrion Co. stock logo
ATRI
Atrion
$459.92
$459.06
$274.98
$503.24
$809.46M0.6923,283 shsN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$20.00
$19.98
$12.26
$20.57
$843.96M0.74765,906 shs4,300 shs
Pulmonx Corporation stock logo
LUNG
Pulmonx
$2.80
+6.1%
$3.18
$2.50
$9.37
$112.73M0.45304,586 shs121,406 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
-0.76%-3.75%-9.73%+3.04%+33.25%
Atrion Co. stock logo
ATRI
Atrion
0.00%0.00%0.00%0.00%+1.50%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.00%0.00%0.00%0.00%0.00%
Pulmonx Corporation stock logo
LUNG
Pulmonx
-4.86%+1.93%-16.72%-53.85%-59.32%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AtriCure, Inc. stock logo
ATRC
AtriCure
3.263 of 5 stars
3.55.00.00.01.32.50.6
Atrion Co. stock logo
ATRI
Atrion
N/AN/AN/AN/AN/AN/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/AN/AN/AN/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
3.0138 of 5 stars
3.33.00.00.02.03.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
3.00
Buy$50.6760.29% Upside
Atrion Co. stock logo
ATRI
Atrion
0.00
N/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.00
N/AN/AN/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
2.63
Moderate Buy$11.53311.61% Upside

Current Analyst Ratings Breakdown

Latest ATRC, CSII, ATRI, and LUNG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.15
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
4/30/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$60.00 ➝ $60.00
4/30/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $58.00
4/30/2025
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$51.00 ➝ $44.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$480.08M3.26N/AN/A$9.46 per share3.34
Atrion Co. stock logo
ATRI
Atrion
$181.60M4.46$19.68 per share23.37$138.02 per share3.33
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$239.84M3.52N/AN/A$6.12 per share3.27
Pulmonx Corporation stock logo
LUNG
Pulmonx
$83.79M1.35N/AN/A$2.17 per share1.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$44.70M-$0.81N/AN/AN/A-7.95%-5.68%-4.34%7/29/2025 (Estimated)
Atrion Co. stock logo
ATRI
Atrion
$19.41M$10.6443.23N/A10.60%7.75%7.12%N/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
-$36.93M-$0.97N/AN/AN/A-15.79%-15.39%-11.93%N/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)

Latest ATRC, CSII, ATRI, and LUNG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$0.40N/AN/AN/A$23.46 millionN/A
7/29/2025Q2 2025
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.15N/AN/AN/A$130.17 millionN/A
5/7/2025Q1 2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 million
4/29/2025Q1 2025
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.25-$0.14+$0.11-$0.14$122.92 million$123.62 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Atrion Co. stock logo
ATRI
Atrion
$8.801.91%N/A82.71%21 Years
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.16
4.11
2.88
Atrion Co. stock logo
ATRI
Atrion
N/A
9.18
3.06
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.08
6.04
4.92
Pulmonx Corporation stock logo
LUNG
Pulmonx
0.38
4.97
4.29

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Atrion Co. stock logo
ATRI
Atrion
66.19%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
86.61%
Pulmonx Corporation stock logo
LUNG
Pulmonx
91.04%

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
3.50%
Atrion Co. stock logo
ATRI
Atrion
22.82%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
3.80%
Pulmonx Corporation stock logo
LUNG
Pulmonx
6.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,30049.51 million47.77 millionOptionable
Atrion Co. stock logo
ATRI
Atrion
7201.76 million1.36 millionNot Optionable
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
78042.20 million40.59 millionOptionable
Pulmonx Corporation stock logo
LUNG
Pulmonx
25040.26 million37.52 millionOptionable

Recent News About These Companies

Pulmonx Corporation (LUNG) Stock Forecasts
Q1 2025 Pulmonx Corp Earnings Call
Pulmonx Reports First Quarter 2025 Financial Results
Pulmonx's Earnings Outlook

New MarketBeat Followers Over Time

Media Sentiment Over Time

AtriCure stock logo

AtriCure NASDAQ:ATRC

$31.61 +0.07 (+0.22%)
As of 02:56 PM Eastern

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Atrion stock logo

Atrion NASDAQ:ATRI

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. The company's ophthalmic products consist of a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. It manufactures products for safe needle and scalpel blade containment; inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Cardiovascular Systems stock logo

Cardiovascular Systems NASDAQ:CSII

Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.

Pulmonx stock logo

Pulmonx NASDAQ:LUNG

$2.80 +0.16 (+6.06%)
As of 02:55 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.